Trevena Inc (NASDAQ:TRVN) – Research analysts at Oppenheimer issued their FY2022 earnings estimates for shares of Trevena in a note issued to investors on Monday. Oppenheimer analyst D. Archila anticipates that the biopharmaceutical company will earn $0.73 per share for the year. Oppenheimer currently has a “Buy” rating and a $5.00 target price on the stock.
Several other brokerages have also recently commented on TRVN. HC Wainwright boosted their price objective on shares of Trevena to $7.00 and gave the company a “buy” rating in a research note on Thursday, March 8th. Zacks Investment Research cut shares of Trevena from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a research note on Saturday, January 20th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. Trevena has a consensus rating of “Buy” and a consensus target price of $7.06.
Trevena (NASDAQ:TRVN) last issued its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.02.
A number of institutional investors have recently made changes to their positions in the business. Millennium Management LLC bought a new stake in Trevena during the fourth quarter valued at approximately $130,000. Goldman Sachs Group Inc. lifted its position in Trevena by 343.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 195,253 shares of the biopharmaceutical company’s stock valued at $312,000 after purchasing an additional 151,257 shares during the last quarter. Virtu Financial LLC lifted its position in Trevena by 1,546.1% during the fourth quarter. Virtu Financial LLC now owns 191,701 shares of the biopharmaceutical company’s stock valued at $307,000 after purchasing an additional 180,055 shares during the last quarter. Bourgeon Capital Management LLC lifted its position in Trevena by 59.3% during the fourth quarter. Bourgeon Capital Management LLC now owns 137,800 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 51,300 shares during the last quarter. Finally, American Century Companies Inc. bought a new stake in Trevena during the fourth quarter valued at approximately $135,000. Institutional investors and hedge funds own 52.50% of the company’s stock.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.